Evidence-Based Reviews

Dissecting melancholia with evidence-based biomarker tools

Author and Disclosure Information

 

References

  • a decrease in the production of BDNF
  • increased susceptibility to neuropsychiatric disorders, including depression, anxiety disorder, and bipolar disorder (Figure 7).32

People with the MM allele have been found to have a small hippocampal neuronal density and poor hippocampus-dependent memory function in neuroimaging studies.23 They also displayed diminished ventromedial prefrontal cortex volume and presented with aversive memory extinction deficit (ie, “holding grudges”).

Another neurotrophic factor, vascular endothelial growth factor (VEGF), is a survival factor for endothelial cells and neurons and a modulator of synaptic transmission. Understanding the molecular and cellular specificity of antidepressant-induced VEGF will be critical to determine its potential as a therapeutic target in depression.33 Delineating the relationship between VEGF and depression has, ultimately, the potential to shed light on the still elusive neural mechanisms that underlie the pathophysiology of depression and the mechanisms by which antidepressants exert their effects.34

Genetic polymorphisms in monoamine receptors (5-HT2A), transporters (SERTPR, 5-HTTLPR, STin2, rs25531, SLC6A4), and regulatory enzymes should not be overlooked.35 There is reproducible evidence that variability in these polymorphisms are associated with variability in:

  • vulnerability to depression
  • the response to treatment with existing antidepressant medications.1

Most studies that look at changes in neuronal circuitry focus on the integrity of synaptic connections between the frontal cortex and limbic system; few of them have closely examined the importance of the anatomic proximity of the 2 regions. It might be that having an amygdala that is relatively closer to the frontal cortex and the hippocampus reduces a person’s risk of depression, and vice versa. This association needs to be investigated further with imaging studies.

Environmental risk factors. The brain is thought to be plastic until age 30.5 Plasticity diminishes with age after age 7—except for the hippocampus, which can regenerate throughout life.36 Early life experiences play an important role in forming synaptic connections between the frontal cortex and the limbic system, through a process known as fear conditioning.

Children learn early in life which stimuli are to be perceived as threatening or aversive and how to respond to best preserves their safety and internal sense of well-being. Those who grow up in a hostile environment learn to perceive more stimuli as threatening than children who grow up in a nurturing environment.32 It is possible that the amygdala is larger in children who grow up in less-than-ideal circumstances because this region is constantly being recruited—at the expense of the more rational frontal cortex.

Evidence suggests that these conditions reduce hippocampal neurogenesis37:

  • increasing age
  • substance abuse (opiates and methamphetamines)
  • inadequate housing
  • minimal physical activity
  • little opportunity for social stimulation
  • minimal learning experience.

Bottom Line

Depression has been understood as a neurotransmitter deficiency in the brain; treatments were engineered to increase release, or block degradation, of those neurotransmitters. Novel theories—all interconnected—of the neuroanatomical pathophysiology of depression focus more on differences in neuron density in the brain; effects of stress on neurogenesis and neuronal cell apoptosis; alterations in feedback pathways connecting the pre-frontal cortex to the limbic system; and the role of pro-inflammatory mediators evoked during the stress response.

Related Resources

  • Fuchs E. Neurogenesis in the adult brain: is there an association with mental disorders? Eur Arch Psychiatry Clin Neurosci. 2007;257(5):247-249.
  • Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004; 161(11):1957-1966.

Disclosure

The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

Acknowledgement

Anita Rao, second-year medical student, Stritch School of Medicine, Loyola University, Chicago, Illinois, assisted in the preparation of this manuscript.

Pages

Recommended Reading

Women’s sexuality diminished by psoriasis
MDedge Psychiatry
Levomilnacipran for the treatment of major depressive disorder
MDedge Psychiatry
Discharging your patients who display contingency-based suicidality: 6 steps
MDedge Psychiatry
Six percent of adolescents report psychotropic use in past month
MDedge Psychiatry
Pediatric epilepsy surgery improved mood, behavior in some patients
MDedge Psychiatry
SSRI use in pregnancy doesn’t raise autism risk
MDedge Psychiatry
Abnormal neural responses to emotional stimuli found in bipolar, depression
MDedge Psychiatry
Luteal-phase antidepressant an option in recalcitrant PMS, PMDD
MDedge Psychiatry
For trichotillomania, try behavioral therapy before drugs
MDedge Psychiatry
Treating youngsters’ depression means going off the FDA grid
MDedge Psychiatry

Related Articles